Benzinga - by Benzinga Insights, Benzinga Staff Writer. Bruker (NASDAQ:BRKR) has announced an acquisition of PhenomeX (NASDAQ:CELL) that is expected to be completed in Q4 of 2023.
Under the terms of the agreement, Bruker has agreed to give PhenomeX $108.00 million in cash in exchange for CELL stock.
About The Companies Involved Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST).
PhenomeX Inc is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes..
How An Acquisition Works An acquisition is when one company, called the acquiring company, buys most or all of another company's, or target company's, shares to gain ownership. Buying more than 50% of a company's stock allows the the acquirer to make decisions without the approval of the company's shareholders.
An acquisition can potentially lead to a merger with the parent company, which makes it similar to a merger. This is why the two terms are commonly grouped together as mergers and acquisitions (M&A). However, in a merger, the leadership & operations of both companies usually change dramatically, while during an acquisition this is less likely to happen.
Make sure to follow our mergers & acquisitions calendar to stay-up-to-date on the most recent M&A deals.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.